<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03612492</url>
  </required_header>
  <id_info>
    <org_study_id>Esmolol vs Lidocaine on OTI</org_study_id>
    <nct_id>NCT03612492</nct_id>
  </id_info>
  <brief_title>The Effects of Lidocaine and Esmolol on Attenuation of Hemodynamic Response to Orotracheal Intubation</brief_title>
  <official_title>The Effects of Lidocaine and Esmolol on Attenuation of Hemodynamic Response to Orotracheal Intubation: A Double-blind, Randomized, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Base</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Base</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to compare the hemodynamic response during laryngoscopy and
      orotracheal intubation using continuous infusion of lidocaine and esmolol in patients
      undergoing general anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Esmolol is a selective beta-blocker of fast action that antagonizes beta-1 adrenergic
      receptors. Venous lidocaine is the agent most used to attenuate the hemodynamic response to
      laryngoscopy and intubation, in addition to cough reflex.

      Objective: To compare the hemodynamic response during laryngoscopy and orotracheal intubation
      using continuous infusion of lidocaine and esmolol.

      Methods: Randomized, double masked clinical trial aims to compare the effect of esmolol and
      lidocaine on orotracheal intubation. All patients will receive balanced general anesthesia.
      One group (EG) will receive bolus esmolol of 1.5mg / kg in 10 min following by continuous
      infusion at a rate of 0.1mg / kg / min. The lidocaine (LG) group will receive lidocaine bolus
      of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.

      Data on hemodynamic changes, reaction to laryngoscopy, conditions at intubation and adverse
      events will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with tachycardia after intubation</measure>
    <time_frame>12 minutes</time_frame>
    <description>Analysis of the incidence of tachycardia after intubation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>12 minutes</time_frame>
    <description>Hemodynamic stability analysis through the incidence of tachycardia, hypertension, bradycardia, hypotension</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hemodynamic Instability</condition>
  <arm_group>
    <arm_group_label>Esmolol Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive esmolol during induction of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive lidocaine during induction of anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.</description>
    <arm_group_label>Esmolol Group</arm_group_label>
    <arm_group_label>Lidocaine Group</arm_group_label>
    <other_name>Beta blocker</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.</description>
    <arm_group_label>Esmolol Group</arm_group_label>
    <arm_group_label>Lidocaine Group</arm_group_label>
    <other_name>Local anesthetic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 18 and 70 years

          -  Physical State 1, 2 or 3 of the American Society of Anesthesiology (ASA)

          -  Electively or urgently scheduled for surgery requiring general anesthesia, with
             programming of orotracheal intubation via direct laryngoscopy at the Base Hospital of
             the Federal District.

        Exclusion Criteria:

          -  Patients younger than 18 and over 70 years of age

          -  Patients with contraindications or history of hypersensitivity to the drugs involved
             in the study

          -  Patients with coronary ischemic disease

          -  Patients with atrioventricular block at any grade

          -  Patients with diagnosed cardiac arrhythmias

          -  Patients with heart failure

          -  Patients who are beta-blockers or calcium channel blockers

          -  Patients with renal insufficiency of any kind

          -  Patients with difficulty predicting orotracheal intubation

          -  Patients with BMI ≥ 35 kg / m²

          -  Patients who underwent neuroaxis block before anesthetic induction

          -  Patients who refuse to participate in the study after submitting the informed consent
             form

          -  Patients requiring two or more attempts of laryngoscopy for positioning of the
             orotracheal tube

          -  Patients with asthma

          -  Any other condition that, in the opinion of the researcher, may pose a risk to the
             patient or interfere with the objectives of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de Base do Distrito Federal</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>70680250</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamil Elias, MD</last_name>
      <phone>556133151588</phone>
      <email>uamphbdf@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Viviane Rezende, MD</last_name>
      <phone>556133151331</phone>
      <email>vrezende@icab.med.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Singh S, Laing EF, Owiredu WK, Singh A. Comparison of esmolol and lidocaine for attenuation of cardiovascular stress response to laryngoscopy and endotracheal intubation in a Ghanaian population. Anesth Essays Res. 2013 Jan-Apr;7(1):83-8. doi: 10.4103/0259-1162.114008.</citation>
    <PMID>25885726</PMID>
  </reference>
  <reference>
    <citation>Mendonça FT, de Queiroz LM, Guimarães CC, Xavier AC. Effects of lidocaine and magnesium sulfate in attenuating hemodynamic response to tracheal intubation: single-center, prospective, double-blind, randomized study. Braz J Anesthesiol. 2017 Jan - Feb;67(1):50-56. doi: 10.1016/j.bjane.2015.08.004. Epub 2016 Nov 22.</citation>
    <PMID>28017170</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>May 24, 2019</last_update_submitted>
  <last_update_submitted_qc>May 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Base</investigator_affiliation>
    <investigator_full_name>Fabricio Tavares Mendonca</investigator_full_name>
    <investigator_title>Preceptor of Medical Residency in Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>esmolol</keyword>
  <keyword>lidocaine</keyword>
  <keyword>intubation</keyword>
  <keyword>hemodynamic response</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

